Related Experiment Video
Updated: Dec 23, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
[Corrigendum] Novel polygodial analogs P3 and P27: Efficacious therapeutic agents disrupting mitochondrial function
Jorge De La Chapa1, Prajjal Kanti Singha2, Mckay Sallaway3
1Department of Comprehensive Dentistry, University of Texas Health Science Center at San Antonio School of Dentistry, San Antonio, TX 78229-3900, USA.
Abstract:
After the publication of the above article, the authors have realized that they failed to properly acknowledge the work performed by their Center for Innovative Drug Discovery High Throughput Screening Core Facility in the paper. The Declarations section of their paper should therefore have also included the following statement: "The UT Health San Antonio Center for Innovative Drug Discovery HTS Facility was funded in part by the Cancer Prevention Research Institute of Texas (CPRIT; grant no. RP160844)". The authors regret their oversight in failing to include this information in the Declarations section of their paper. [the original article was published in International Journal of Oncology 53: 2627-2636, 2018; DOI: 10.3892/ijo.2018.4585].
Insights
This article corrects an omission in a previous publication regarding funding for the High Throughput Screening Core Facility. The facility received partial funding from the Cancer Prevention Research Institute of Texas.
Area of Science:
- Oncology
- Drug Discovery
- Biomedical Research
Background:
- A previous study published in the International Journal of Oncology requires a correction.
- The original article did not fully acknowledge the contributions of a specific research facility.
Purpose of the Study:
- To amend the Declarations section of the original publication.
- To properly credit the Center for Innovative Drug Discovery High Throughput Screening Core Facility.
Main Methods:
- Review of the original publication's Declarations section.
- Identification of the omitted acknowledgment statement.
Main Results:
- The High Throughput Screening Core Facility at UT Health San Antonio was partially funded by the Cancer Prevention Research Institute of Texas (CPRIT).
- The specific grant number for this funding was RP160844.
Conclusions:
- The authors express regret for the oversight in the original publication.
- This correction ensures accurate reporting of research support and collaborations.
Related Concept Videos
Abnormal Proliferation
Targeted Cancer Therapies
There are several types of targeted therapies against...
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Drugs that Stabilize Microtubules

